Tirzepatide Cost in 2026: Every Path, Ranked
Tirzepatide is the active ingredient in Mounjaro (FDA-approved for type 2 diabetes) and Zepbound (FDA-approved for weight loss) — both made by Eli Lilly. It is also the molecule still produced in limited quantities by 503A compounding pharmacies. Cash-pay prices in May 2026 range from $299/month (compounded) up to $1,069/month (cash WAC). This page covers every channel — pick the right one for your situation.
Every tirzepatide channel, ranked by typical cash-pay cost
| Channel | Brand | Monthly |
|---|---|---|
| Compounded telehealth | Generic tirzepatide | $299 |
| LillyDirect self-pay vials | Zepbound (2.5 / 5 mg) | $349 |
| Branded telehealth | Zepbound pens | $499 |
| Branded telehealth | Mounjaro pens | $499 |
| Cash retail (WAC) | Zepbound pens | $1,059 |
| Cash retail (WAC) | Mounjaro pens | $1,069 |
Insurance copay paths excluded from this table — see /glp-1-savings-cards for that side.
Mounjaro or Zepbound? Two answers depending on your diagnosis
- If you have type 2 diabetes: Mounjaro is usually cheaper because your insurance is more likely to cover it. Use the Mounjaro Savings Card to drop the copay further.
- If you do not have type 2 diabetes: Zepbound. The LillyDirect self-pay vial program is the cheapest legitimate cash-pay path to tirzepatide and only exists for Zepbound, not Mounjaro.
- Either way: the molecule in the syringe is identical — same active ingredient, same dosing, same titration schedule.
LillyDirect Zepbound vials ($349/mo, lower doses)
LillyDirect is Eli Lilly's direct-to-consumer storefront. The Zepbound vial product covers the 2.5 mg and 5 mg starting doses at $349/month — the cheapest legitimate path to branded tirzepatide as of May 2026.
Higher doses (7.5 mg, 10 mg, 12.5 mg, 15 mg) are not in the LillyDirect self-pay vial menu. Patients who titrate above 5 mg and want to stay self-pay generally switch to branded telehealth, compounded (where legal), or insurance-covered pens.
Visit LillyDirect →Compounded tirzepatide (~$299/mo, where legal)
Compounded tirzepatide is a personalized formulation made by a US-licensed 503A compounding pharmacy. During the 2023–2024 FDA shortage, this was the cheapest path to tirzepatide for most cash-pay patients. The FDA officially ended the shortage in late 2024, narrowing the regulatory shield for most compounded versions.
As of May 2026, some 503A pharmacies still produce case-by-case formulations through licensed telehealth platforms, but availability and legal posture vary by state. Pricing typically lands in the $299/month range. Verify the pharmacy is US-licensed and PCAB-accredited; avoid international "research peptide" vendors — those are not legal for human use and have unverified purity.
Branded tirzepatide via telehealth
Branded Zepbound or Mounjaro pens are available through major telehealth platforms when LillyDirect and compounded paths are not available or appropriate. Pricing typically runs around $499/month for Zepbound and $499/month for Mounjaro, including the prescriber visit and shipment.
Major options as of May 2026:
- Hims & Hers — fast onboarding, in-house pharmacy
- Ro — Body Program with coaching
- Lemonaid Health — pay per visit
- LifeMD — wide GLP-1 menu
Full side-by-side at telehealth provider comparison.
Should you use tirzepatide or semaglutide?
The two big GLP-1 molecules of 2026 are tirzepatide (Zepbound, Mounjaro) and semaglutide (Wegovy, Ozempic, oral Wegovy). Tirzepatide is meaningfully more effective per the trial data — 22.5% peak weight loss in SURMOUNT-1 vs 14.9% for Wegovy in STEP-1. The 2024–2025 SURMOUNT-5 trial confirmed tirzepatide's edge in head-to-head data.
Semaglutide has the longer real-world track record (Wegovy approved 2021 vs Zepbound 2023), broader telehealth supply, and the option of an oral pill (oral Wegovy 25 mg, FDA-approved early 2026). For some patients GI tolerability is better. Run the comparison directly:
- Wegovy vs Zepbound — semaglutide vs tirzepatide head-to-head
- Cheapest GLP-1 — full ranking with $/lb breakdown
- How to Get Zepbound Without Insurance
- How to Get Mounjaro Without Insurance
Frequently asked questions
How much does tirzepatide cost without insurance in 2026?
It depends on which brand and channel. The cheapest legitimate path is Zepbound LillyDirect self-pay vials at around $349/month for the 2.5 mg and 5 mg starting doses. Compounded tirzepatide via licensed telehealth runs around $299/month where still available. Branded Zepbound or Mounjaro through telehealth is around $499/month. Cash retail (full WAC) is $1,059/month for Zepbound or $1,069/month for Mounjaro.
What is the difference between Mounjaro and Zepbound?
They are the same molecule (tirzepatide) with the same dosing schedule, sold under different brand names for different FDA-approved indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Eli Lilly only offers self-pay vials for Zepbound, not Mounjaro, so for cash-pay patients the brand choice is largely a coverage and pricing question, not a clinical one.
Is compounded tirzepatide still legal in 2026?
It is in a narrower regulatory zone than during the 2023–2024 FDA shortage period. The FDA officially ended the tirzepatide drug shortage in late 2024, removing the regulatory shield that had let 503A pharmacies compound tirzepatide at scale. As of May 2026, some 503A pharmacies still produce personalized formulations on a case-by-case basis through licensed telehealth, but availability and legal posture vary by state. Only use US-licensed, PCAB-accredited 503A pharmacies — never international "research peptide" sources, which are not legal for human use.
Is tirzepatide more effective than semaglutide for weight loss?
In head-to-head data, yes. Zepbound (tirzepatide) reached 22.5% peak weight loss in SURMOUNT-1, vs 14.9% for Wegovy (semaglutide) in STEP-1. The SURMOUNT-5 trial directly compared the two molecules and found tirzepatide produced more weight loss at every dose. The trade-off is GI side effects can be more pronounced at higher tirzepatide doses, and individual tolerability varies.
Why are LillyDirect vials cheaper than Zepbound pens?
Two reasons. First, the manufacturing path: pre-filled auto-injector pens are more expensive to produce than vials of the same drug. Second, distribution: LillyDirect is direct-to-consumer (no pharmacy benefit manager, no wholesaler markup), while Zepbound pens go through traditional distribution. The trade-off the patient takes for the discount is a manual syringe draw rather than a pre-filled pen. As of May 2026, LillyDirect self-pay vials are only offered for the 2.5 mg and 5 mg doses; higher doses still go through pen distribution.
Can I get tirzepatide through Mounjaro to use it for weight loss?
Possible but usually not the cheapest path. If you have a documented type 2 diabetes diagnosis on your chart, your insurance is more likely to cover Mounjaro, and the Mounjaro Savings Card can drop the copay to ~$25/month. If you do not have type 2 diabetes, almost no insurer will cover Mounjaro, and the cash-pay options for Mounjaro are more expensive than for Zepbound (no LillyDirect vial program). The /mounjaro-without-insurance page covers this in detail.
Are there any other tirzepatide-like molecules in development?
Yes. Eli Lilly is developing retatrutide, a triple GLP-1/GIP/glucagon agonist that has shown ~24% peak weight loss in Phase 2 and is in Phase 3 trials. Novo Nordisk filed CagriSema (cagrilintide + semaglutide) for FDA approval in late 2025 with ~20% peak weight loss in REDEFINE-1. Both are next-generation drugs that may reshape pricing once approved. Sign up for the GLP1Cost newsletter below to get notified on FDA decisions.
Stay ahead of every GLP-1 development
We'll email you when something actually matters: new FDA approvals (Foundayo, CagriSema, retatrutide), pricing drops at LillyDirect/NovoCare, telehealth deals, clinical trial results, FDA recalls, and insurance policy changes. ~1-2 emails/month. No filler.